Composite end points in clinical trials

JAMA. 2010 May 5;303(17):1698; author reply 1698. doi: 10.1001/jama.2010.522.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Endpoint Determination*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Kaplan-Meier Estimate
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic*
  • Rosiglitazone
  • Thiazolidinediones / therapeutic use

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone